Global Therapeutic Radioligands Drug Market Growth (Status and Outlook) 2026-2032

June 2026 | 126 pages | ID: G8E9D7A15F57EN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Therapeutic Radioligands Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

United States market for Therapeutic Radioligands Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Therapeutic Radioligands Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Therapeutic Radioligands Drug is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Therapeutic Radioligands Drug players cover Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the ?Therapeutic Radioligands Drug Industry Forecast? looks at past sales and reviews total world Therapeutic Radioligands Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Therapeutic Radioligands Drug sales for 2026 through 2032. With Therapeutic Radioligands Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Therapeutic Radioligands Drug industry.

This Insight Report provides a comprehensive analysis of the global Therapeutic Radioligands Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Therapeutic Radioligands Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Therapeutic Radioligands Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Therapeutic Radioligands Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Therapeutic Radioligands Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Therapeutic Radioligands Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:
  • Beta-emitting
  • Targeted Alpha Therapy
Segmentation by Application:
  • Solid Tumor
  • Non Hodgkin Lymphoma
This report also splits the market by region:
  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
  • Bayer
  • Novartis
  • Lantheus
  • Aurobindo Pharma
  • Mundipharma
  • China Isotope & Radiation
  • Curium Pharmaceuticals
  • Gilead Sciences
  • Clarity Pharmaceuticals
  • Curasight
  • Nordic Nanovector
  • Philogen
  • RadioMedix
  • Telix Pharmaceuticals
  • Orano Med
  • Actinium Pharmaceuticals
  • Y-mAbs Therapeutics
  • Fusion Pharmaceuticals
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Therapeutic Radioligands Drug Market Size (2021-2032)
  2.1.2 Therapeutic Radioligands Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
  2.1.3 World Current & Future Analysis for Therapeutic Radioligands Drug by Country/Region (2021, 2025 & 2032)
2.2 Therapeutic Radioligands Drug Segment by Type
  2.2.1 Beta-emitting
  2.2.2 Targeted Alpha Therapy
  2.2.3 Therapeutic Radioligands Drug Market Size by Type
    2.2.3.1 Therapeutic Radioligands Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
    2.2.3.2 Global Therapeutic Radioligands Drug Market Size Market Share by Type (2021-2026)
2.3 Therapeutic Radioligands Drug Segment by Application
  2.3.1 Solid Tumor
  2.3.2 Non Hodgkin Lymphoma
  2.3.3 Therapeutic Radioligands Drug Market Size by Application
    2.3.3.1 Therapeutic Radioligands Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
    2.3.3.2 Global Therapeutic Radioligands Drug Market Size Market Share by Application (2021-2026)

3 THERAPEUTIC RADIOLIGANDS DRUG MARKET SIZE BY PLAYER

3.1 Therapeutic Radioligands Drug Market Size Market Share by Player
  3.1.1 Global Therapeutic Radioligands Drug Revenue by Player (2021-2026)
  3.1.2 Global Therapeutic Radioligands Drug Revenue Market Share by Player (2021-2026)
3.2 Global Therapeutic Radioligands Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 THERAPEUTIC RADIOLIGANDS DRUG BY REGION

4.1 Therapeutic Radioligands Drug Market Size by Region (2021-2026)
4.2 Global Therapeutic Radioligands Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Therapeutic Radioligands Drug Market Size Growth (2021-2026)
4.4 APAC Therapeutic Radioligands Drug Market Size Growth (2021-2026)
4.5 Europe Therapeutic Radioligands Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa Therapeutic Radioligands Drug Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Therapeutic Radioligands Drug Market Size by Country (2021-2026)
5.2 Americas Therapeutic Radioligands Drug Market Size by Type (2021-2026)
5.3 Americas Therapeutic Radioligands Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Therapeutic Radioligands Drug Market Size by Region (2021-2026)
6.2 APAC Therapeutic Radioligands Drug Market Size by Type (2021-2026)
6.3 APAC Therapeutic Radioligands Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Therapeutic Radioligands Drug Market Size by Country (2021-2026)
7.2 Europe Therapeutic Radioligands Drug Market Size by Type (2021-2026)
7.3 Europe Therapeutic Radioligands Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Therapeutic Radioligands Drug by Region (2021-2026)
8.2 Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL THERAPEUTIC RADIOLIGANDS DRUG MARKET FORECAST

10.1 Global Therapeutic Radioligands Drug Forecast by Region (2027-2032)
  10.1.1 Global Therapeutic Radioligands Drug Forecast by Region (2027-2032)
  10.1.2 Americas Therapeutic Radioligands Drug Forecast
  10.1.3 APAC Therapeutic Radioligands Drug Forecast
  10.1.4 Europe Therapeutic Radioligands Drug Forecast
  10.1.5 Middle East & Africa Therapeutic Radioligands Drug Forecast
10.2 Americas Therapeutic Radioligands Drug Forecast by Country (2027-2032)
  10.2.1 United States Market Therapeutic Radioligands Drug Forecast
  10.2.2 Canada Market Therapeutic Radioligands Drug Forecast
  10.2.3 Mexico Market Therapeutic Radioligands Drug Forecast
  10.2.4 Brazil Market Therapeutic Radioligands Drug Forecast
10.3 APAC Therapeutic Radioligands Drug Forecast by Region (2027-2032)
  10.3.1 China Therapeutic Radioligands Drug Market Forecast
  10.3.2 Japan Market Therapeutic Radioligands Drug Forecast
  10.3.3 Korea Market Therapeutic Radioligands Drug Forecast
  10.3.4 Southeast Asia Market Therapeutic Radioligands Drug Forecast
  10.3.5 India Market Therapeutic Radioligands Drug Forecast
  10.3.6 Australia Market Therapeutic Radioligands Drug Forecast
10.4 Europe Therapeutic Radioligands Drug Forecast by Country (2027-2032)
  10.4.1 Germany Market Therapeutic Radioligands Drug Forecast
  10.4.2 France Market Therapeutic Radioligands Drug Forecast
  10.4.3 UK Market Therapeutic Radioligands Drug Forecast
  10.4.4 Italy Market Therapeutic Radioligands Drug Forecast
  10.4.5 Russia Market Therapeutic Radioligands Drug Forecast
10.5 Middle East & Africa Therapeutic Radioligands Drug Forecast by Region (2027-2032)
  10.5.1 Egypt Market Therapeutic Radioligands Drug Forecast
  10.5.2 South Africa Market Therapeutic Radioligands Drug Forecast
  10.5.3 Israel Market Therapeutic Radioligands Drug Forecast
  10.5.4 Turkey Market Therapeutic Radioligands Drug Forecast
10.6 Global Therapeutic Radioligands Drug Forecast by Type (2027-2032)
10.7 Global Therapeutic Radioligands Drug Forecast by Application (2027-2032)
  10.7.1 GCC Countries Market Therapeutic Radioligands Drug Forecast

11 KEY PLAYERS ANALYSIS

11.1 Bayer
  11.1.1 Bayer Company Information
  11.1.2 Bayer Therapeutic Radioligands Drug Product Offered
  11.1.3 Bayer Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.1.4 Bayer Main Business Overview
  11.1.5 Bayer Latest Developments
11.2 Novartis
  11.2.1 Novartis Company Information
  11.2.2 Novartis Therapeutic Radioligands Drug Product Offered
  11.2.3 Novartis Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.2.4 Novartis Main Business Overview
  11.2.5 Novartis Latest Developments
11.3 Lantheus
  11.3.1 Lantheus Company Information
  11.3.2 Lantheus Therapeutic Radioligands Drug Product Offered
  11.3.3 Lantheus Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.3.4 Lantheus Main Business Overview
  11.3.5 Lantheus Latest Developments
11.4 Aurobindo Pharma
  11.4.1 Aurobindo Pharma Company Information
  11.4.2 Aurobindo Pharma Therapeutic Radioligands Drug Product Offered
  11.4.3 Aurobindo Pharma Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.4.4 Aurobindo Pharma Main Business Overview
  11.4.5 Aurobindo Pharma Latest Developments
11.5 Mundipharma
  11.5.1 Mundipharma Company Information
  11.5.2 Mundipharma Therapeutic Radioligands Drug Product Offered
  11.5.3 Mundipharma Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.5.4 Mundipharma Main Business Overview
  11.5.5 Mundipharma Latest Developments
11.6 China Isotope & Radiation
  11.6.1 China Isotope & Radiation Company Information
  11.6.2 China Isotope & Radiation Therapeutic Radioligands Drug Product Offered
  11.6.3 China Isotope & Radiation Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.6.4 China Isotope & Radiation Main Business Overview
  11.6.5 China Isotope & Radiation Latest Developments
11.7 Curium Pharmaceuticals
  11.7.1 Curium Pharmaceuticals Company Information
  11.7.2 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Offered
  11.7.3 Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.7.4 Curium Pharmaceuticals Main Business Overview
  11.7.5 Curium Pharmaceuticals Latest Developments
11.8 Gilead Sciences
  11.8.1 Gilead Sciences Company Information
  11.8.2 Gilead Sciences Therapeutic Radioligands Drug Product Offered
  11.8.3 Gilead Sciences Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.8.4 Gilead Sciences Main Business Overview
  11.8.5 Gilead Sciences Latest Developments
11.9 Clarity Pharmaceuticals
  11.9.1 Clarity Pharmaceuticals Company Information
  11.9.2 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Offered
  11.9.3 Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.9.4 Clarity Pharmaceuticals Main Business Overview
  11.9.5 Clarity Pharmaceuticals Latest Developments
11.10 Curasight
  11.10.1 Curasight Company Information
  11.10.2 Curasight Therapeutic Radioligands Drug Product Offered
  11.10.3 Curasight Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.10.4 Curasight Main Business Overview
  11.10.5 Curasight Latest Developments
11.11 Nordic Nanovector
  11.11.1 Nordic Nanovector Company Information
  11.11.2 Nordic Nanovector Therapeutic Radioligands Drug Product Offered
  11.11.3 Nordic Nanovector Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.11.4 Nordic Nanovector Main Business Overview
  11.11.5 Nordic Nanovector Latest Developments
11.12 Philogen
  11.12.1 Philogen Company Information
  11.12.2 Philogen Therapeutic Radioligands Drug Product Offered
  11.12.3 Philogen Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.12.4 Philogen Main Business Overview
  11.12.5 Philogen Latest Developments
11.13 RadioMedix
  11.13.1 RadioMedix Company Information
  11.13.2 RadioMedix Therapeutic Radioligands Drug Product Offered
  11.13.3 RadioMedix Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.13.4 RadioMedix Main Business Overview
  11.13.5 RadioMedix Latest Developments
11.14 Telix Pharmaceuticals
  11.14.1 Telix Pharmaceuticals Company Information
  11.14.2 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Offered
  11.14.3 Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.14.4 Telix Pharmaceuticals Main Business Overview
  11.14.5 Telix Pharmaceuticals Latest Developments
11.15 Orano Med
  11.15.1 Orano Med Company Information
  11.15.2 Orano Med Therapeutic Radioligands Drug Product Offered
  11.15.3 Orano Med Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.15.4 Orano Med Main Business Overview
  11.15.5 Orano Med Latest Developments
11.16 Actinium Pharmaceuticals
  11.16.1 Actinium Pharmaceuticals Company Information
  11.16.2 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Offered
  11.16.3 Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.16.4 Actinium Pharmaceuticals Main Business Overview
  11.16.5 Actinium Pharmaceuticals Latest Developments
11.17 Y-mAbs Therapeutics
  11.17.1 Y-mAbs Therapeutics Company Information
  11.17.2 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Offered
  11.17.3 Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.17.4 Y-mAbs Therapeutics Main Business Overview
  11.17.5 Y-mAbs Therapeutics Latest Developments
11.18 Fusion Pharmaceuticals
  11.18.1 Fusion Pharmaceuticals Company Information
  11.18.2 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Offered
  11.18.3 Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue, Gross Margin and Market Share (2021-2026)
  11.18.4 Fusion Pharmaceuticals Main Business Overview
  11.18.5 Fusion Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION



LIST OF TABLES

Table 1. Therapeutic Radioligands Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Therapeutic Radioligands Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Beta-emitting
Table 4. Major Players of Targeted Alpha Therapy
Table 5. Therapeutic Radioligands Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Therapeutic Radioligands Drug Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Therapeutic Radioligands Drug Market Size Market Share by Type (2021-2026)
Table 8. Therapeutic Radioligands Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Therapeutic Radioligands Drug Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Therapeutic Radioligands Drug Market Size Market Share by Application (2021-2026)
Table 11. Global Therapeutic Radioligands Drug Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Therapeutic Radioligands Drug Revenue Market Share by Player (2021-2026)
Table 13. Therapeutic Radioligands Drug Key Players Head office and Products Offered
Table 14. Therapeutic Radioligands Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Therapeutic Radioligands Drug Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Therapeutic Radioligands Drug Market Size Market Share by Region (2021-2026)
Table 19. Global Therapeutic Radioligands Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Therapeutic Radioligands Drug Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Therapeutic Radioligands Drug Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Therapeutic Radioligands Drug Market Size Market Share by Country (2021-2026)
Table 23. Americas Therapeutic Radioligands Drug Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Therapeutic Radioligands Drug Market Size Market Share by Type (2021-2026)
Table 25. Americas Therapeutic Radioligands Drug Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Therapeutic Radioligands Drug Market Size Market Share by Application (2021-2026)
Table 27. APAC Therapeutic Radioligands Drug Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Therapeutic Radioligands Drug Market Size Market Share by Region (2021-2026)
Table 29. APAC Therapeutic Radioligands Drug Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Therapeutic Radioligands Drug Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Therapeutic Radioligands Drug Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Therapeutic Radioligands Drug Market Size Market Share by Country (2021-2026)
Table 33. Europe Therapeutic Radioligands Drug Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Therapeutic Radioligands Drug Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Therapeutic Radioligands Drug Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Therapeutic Radioligands Drug Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Therapeutic Radioligands Drug Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Therapeutic Radioligands Drug
Table 39. Key Market Challenges & Risks of Therapeutic Radioligands Drug
Table 40. Key Industry Trends of Therapeutic Radioligands Drug
Table 41. Global Therapeutic Radioligands Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Therapeutic Radioligands Drug Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Therapeutic Radioligands Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Therapeutic Radioligands Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Bayer Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 46. Bayer Therapeutic Radioligands Drug Product Offered
Table 47. Bayer Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Bayer Main Business
Table 49. Bayer Latest Developments
Table 50. Novartis Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 51. Novartis Therapeutic Radioligands Drug Product Offered
Table 52. Novartis Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Novartis Main Business
Table 54. Novartis Latest Developments
Table 55. Lantheus Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 56. Lantheus Therapeutic Radioligands Drug Product Offered
Table 57. Lantheus Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Lantheus Main Business
Table 59. Lantheus Latest Developments
Table 60. Aurobindo Pharma Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 61. Aurobindo Pharma Therapeutic Radioligands Drug Product Offered
Table 62. Aurobindo Pharma Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Aurobindo Pharma Main Business
Table 64. Aurobindo Pharma Latest Developments
Table 65. Mundipharma Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 66. Mundipharma Therapeutic Radioligands Drug Product Offered
Table 67. Mundipharma Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Mundipharma Main Business
Table 69. Mundipharma Latest Developments
Table 70. China Isotope & Radiation Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 71. China Isotope & Radiation Therapeutic Radioligands Drug Product Offered
Table 72. China Isotope & Radiation Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. China Isotope & Radiation Main Business
Table 74. China Isotope & Radiation Latest Developments
Table 75. Curium Pharmaceuticals Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 76. Curium Pharmaceuticals Therapeutic Radioligands Drug Product Offered
Table 77. Curium Pharmaceuticals Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Curium Pharmaceuticals Main Business
Table 79. Curium Pharmaceuticals Latest Developments
Table 80. Gilead Sciences Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 81. Gilead Sciences Therapeutic Radioligands Drug Product Offered
Table 82. Gilead Sciences Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Gilead Sciences Main Business
Table 84. Gilead Sciences Latest Developments
Table 85. Clarity Pharmaceuticals Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 86. Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Offered
Table 87. Clarity Pharmaceuticals Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Clarity Pharmaceuticals Main Business
Table 89. Clarity Pharmaceuticals Latest Developments
Table 90. Curasight Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 91. Curasight Therapeutic Radioligands Drug Product Offered
Table 92. Curasight Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Curasight Main Business
Table 94. Curasight Latest Developments
Table 95. Nordic Nanovector Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 96. Nordic Nanovector Therapeutic Radioligands Drug Product Offered
Table 97. Nordic Nanovector Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Nordic Nanovector Main Business
Table 99. Nordic Nanovector Latest Developments
Table 100. Philogen Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 101. Philogen Therapeutic Radioligands Drug Product Offered
Table 102. Philogen Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Philogen Main Business
Table 104. Philogen Latest Developments
Table 105. RadioMedix Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 106. RadioMedix Therapeutic Radioligands Drug Product Offered
Table 107. RadioMedix Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. RadioMedix Main Business
Table 109. RadioMedix Latest Developments
Table 110. Telix Pharmaceuticals Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 111. Telix Pharmaceuticals Therapeutic Radioligands Drug Product Offered
Table 112. Telix Pharmaceuticals Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Telix Pharmaceuticals Main Business
Table 114. Telix Pharmaceuticals Latest Developments
Table 115. Orano Med Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 116. Orano Med Therapeutic Radioligands Drug Product Offered
Table 117. Orano Med Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Orano Med Main Business
Table 119. Orano Med Latest Developments
Table 120. Actinium Pharmaceuticals Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 121. Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Offered
Table 122. Actinium Pharmaceuticals Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Actinium Pharmaceuticals Main Business
Table 124. Actinium Pharmaceuticals Latest Developments
Table 125. Y-mAbs Therapeutics Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 126. Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Offered
Table 127. Y-mAbs Therapeutics Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Y-mAbs Therapeutics Main Business
Table 129. Y-mAbs Therapeutics Latest Developments
Table 130. Fusion Pharmaceuticals Details, Company Type, Therapeutic Radioligands Drug Area Served and Its Competitors
Table 131. Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Offered
Table 132. Fusion Pharmaceuticals Therapeutic Radioligands Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Fusion Pharmaceuticals Main Business
Table 134. Fusion Pharmaceuticals Latest Developments

LIST OF FIGURES

Figure 1. Therapeutic Radioligands Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Therapeutic Radioligands Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Therapeutic Radioligands Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Therapeutic Radioligands Drug Sales Market Share by Country/Region (2025)
Figure 8. Therapeutic Radioligands Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Therapeutic Radioligands Drug Market Size Market Share by Type in 2025
Figure 10. Therapeutic Radioligands Drug in Solid Tumor
Figure 11. Global Therapeutic Radioligands Drug Market: Solid Tumor (2021-2026) & ($ millions)
Figure 12. Therapeutic Radioligands Drug in Non Hodgkin Lymphoma
Figure 13. Global Therapeutic Radioligands Drug Market: Non Hodgkin Lymphoma (2021-2026) & ($ millions)
Figure 14. Global Therapeutic Radioligands Drug Market Size Market Share by Application in 2025
Figure 15. Global Therapeutic Radioligands Drug Revenue Market Share by Player in 2025
Figure 16. Global Therapeutic Radioligands Drug Market Size Market Share by Region (2021-2026)
Figure 17. Americas Therapeutic Radioligands Drug Market Size 2021-2026 ($ millions)
Figure 18. APAC Therapeutic Radioligands Drug Market Size 2021-2026 ($ millions)
Figure 19. Europe Therapeutic Radioligands Drug Market Size 2021-2026 ($ millions)
Figure 20. Middle East & Africa Therapeutic Radioligands Drug Market Size 2021-2026 ($ millions)
Figure 21. Americas Therapeutic Radioligands Drug Value Market Share by Country in 2025
Figure 22. United States Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 23. Canada Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 24. Mexico Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 25. Brazil Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 26. APAC Therapeutic Radioligands Drug Market Size Market Share by Region in 2025
Figure 27. APAC Therapeutic Radioligands Drug Market Size Market Share by Type (2021-2026)
Figure 28. APAC Therapeutic Radioligands Drug Market Size Market Share by Application (2021-2026)
Figure 29. China Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. Japan Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 31. South Korea Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 32. Southeast Asia Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 33. India Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Australia Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. Europe Therapeutic Radioligands Drug Market Size Market Share by Country in 2025
Figure 36. Europe Therapeutic Radioligands Drug Market Size Market Share by Type (2021-2026)
Figure 37. Europe Therapeutic Radioligands Drug Market Size Market Share by Application (2021-2026)
Figure 38. Germany Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. France Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 40. UK Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 41. Italy Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 42. Russia Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. Middle East & Africa Therapeutic Radioligands Drug Market Size Market Share by Region (2021-2026)
Figure 44. Middle East & Africa Therapeutic Radioligands Drug Market Size Market Share by Type (2021-2026)
Figure 45. Middle East & Africa Therapeutic Radioligands Drug Market Size Market Share by Application (2021-2026)
Figure 46. Egypt Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. South Africa Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 48. Israel Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 49. Turkey Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 50. GCC Countries Therapeutic Radioligands Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. Americas Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 52. APAC Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 53. Europe Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 54. Middle East & Africa Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 55. United States Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 56. Canada Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 57. Mexico Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 58. Brazil Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 59. China Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 60. Japan Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 61. Korea Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 62. Southeast Asia Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 63. India Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 64. Australia Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 65. Germany Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 66. France Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 67. UK Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 68. Italy Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 69. Russia Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 70. Egypt Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 71. South Africa Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 72. Israel Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 73. Turkey Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)
Figure 74. Global Therapeutic Radioligands Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 75. Global Therapeutic Radioligands Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 76. GCC Countries Therapeutic Radioligands Drug Market Size 2027-2032 ($ millions)


More Publications